ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA

本研究的目的是确定单药利妥昔单抗对艾滋病相关性非霍奇金淋巴瘤患者的耐受性和毒性，以及利妥昔单抗对艾滋病相关性非霍奇金淋巴瘤患者外周血淋巴细胞亚群和HIV病毒载量的影响。符合纳入和排除标准并完成治疗前评估的患者将接受每周一次的Rituximab静脉注射。每个课程将在GCRC授课，并在服药结束后进行24小时的观察。最初的登记人数将限制为三名患者。在最后一次抗体注射后，将对所有三名初始患者进行至少两周的观察。如果不超过一名患者出现剂量限制毒性，其余三名患者将被纳入研究。如果在任何时候有两名患者经历了剂量限制性毒性，将不会进行进一步的登记。

The purpose of this study is to determine the tolerance and toxicity of single agent Rituximab in patients with AIDS-associated NHL and the effect of Rituximab on the peripheral blood lymphocytic subsets and HIV viral load in patients with AIDS-associated NHL. Patients who have met the inclusion and exclusion criteria and have completed the pretreatment evaluation will receive Rituximab administered intravenously weekly. Each course will be given at the GCRC with observation for 24 hours after completion of drug administration. Initial enrollment will be limited to three patients. All three initial patients will be observed for at least two weeks following the last antibody infusion. If no more than one patient experiences dose-limiting toxicity, the remaining three patients will be enrolled. If at any time two patients have experienced dose-limiting toxicity, no further enrollment will proceed.